Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120730 | 0.90 | NPY4R (0.37) | MTNR1AMTNR1BDPP8DPP7FAAH | |
| SCHEMBL13105635 | 0.84 | TMEM97 (0.38) | MTNR1AMTNR1BCA12CA1CA2 | |
| SCHEMBL13120727 | 0.80 | ACHE (0.41) | LTA4HACHE | |
| SCHEMBL13416874 | 0.80 | MTNR1A (0.37) | MTNR1AMTNR1BFAAHACHE | |
| SCHEMBL13416894 | 0.79 | MTNR1A (0.39) | MTNR1AMTNR1BFAAHACHE | |
| SCHEMBL13105641 | 0.74 | TMEM97 (0.38) | CA12CA1CA2CA9DPP8 | |
| SCHEMBL13416281 | 0.72 | ACHE (0.44) | DPP8DPP7LTA4HACHEEPOR | |
| SCHEMBL14135115 | 0.72 | ACHE (0.44) | DPP8DPP7LTA4HACHEEPOR | |
| SCHEMBL13416630 | 0.69 | LTA4H (0.39) | LTA4HACHE | |
| SCHEMBL13417055 | 0.69 | ACHE (0.40) | LTA4HACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812039-B2 | analgesic drug for treating neuropathic pain is selected from gabapentine, norvaline, pregabaline, (S)3-isobutylGABA, arginine, thiocitrulline, agmantine, vigabatrin etc. and a NO donar drugs belonging to the classes of aspirin, ibuprofen, paracetamol, naproxen, diclofenac or flurbiprofen | NICOX S.A. (FR) | 2010-10-12 | — | — | US | disclosed |
| US-7696230-B2 | Drugs for chronic pains | NICOX S.A. (FR) | 2010-04-13 | — | — | US | disclosed |
| US-20080113950-A1 | Drugs for chronic pains | NICOX S.A. | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113950-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | MTNR1A 361/4885MTNR1B 181/4885CA12 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.